Drug development in IBD: from novel target identification to early clinical trials

被引:41
作者
Danese, Silvio [1 ]
Fiocchi, Claudio [2 ,3 ]
Panes, Julian [4 ]
机构
[1] Humanitas Univ, Humanitas Res Hosp, Dept Gastroenterol, IBD Ctr, Milan, Italy
[2] Inst Digest Dis, Dept Gastroenterol & Hepatol, Cleveland, OH USA
[3] Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, 9500 Euclid Ave, Cleveland, OH 44195 USA
[4] Hosp Clin Barcelona, Dept Gastroenterol, IDIBAPS, CIBERehd, Barcelona, Spain
关键词
INFLAMMATORY-BOWEL-DISEASE; RECOMBINANT HUMAN INTERLEUKIN-10; ACTIVE CROHNS-DISEASE; TUMOR-NECROSIS-FACTOR; ANIMAL-MODELS; ULCERATIVE-COLITIS; INTESTINAL INFLAMMATION; MAINTENANCE INFLIXIMAB; CYTOKINE PRODUCTION; RANDOMIZED-TRIAL;
D O I
10.1136/gutjnl-2016-311717
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
[No abstract available]
引用
收藏
页码:1233 / 1239
页数:7
相关论文
共 63 条
[1]   In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease [J].
Atreya, Raja ;
Neumann, Helmut ;
Neufert, Clemens ;
Waldner, Maximilian J. ;
Billmeier, Ulrike ;
Zopf, Yurdaguel ;
Willma, Marcus ;
App, Christine ;
Muenster, Tino ;
Kessler, Hermann ;
Maas, Stefanie ;
Gebhardt, Bernd ;
Heimke-Brinck, Ralph ;
Reuter, Eva ;
Doerje, Frank ;
Rau, Tilman T. ;
Uter, Wolfgang ;
Wang, Thomas D. ;
Kiesslich, Ralf ;
Vieth, Michael ;
Hannappel, Ewald ;
Neurath, Markus F. .
NATURE MEDICINE, 2014, 20 (03) :313-318
[2]   Network medicine: a network-based approach to human disease [J].
Barabasi, Albert-Laszlo ;
Gulbahce, Natali ;
Loscalzo, Joseph .
NATURE REVIEWS GENETICS, 2011, 12 (01) :56-68
[3]   Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses [J].
Berg, DJ ;
Davidson, N ;
Kuhn, R ;
Muller, W ;
Menon, S ;
Holland, G ;
ThompsonSnipes, L ;
Leach, MW ;
Rennick, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :1010-1020
[4]   ALPHA-4-BETA-7-INTEGRIN MEDIATES LYMPHOCYTE BINDING TO THE MUCOSAL VASCULAR ADDRESSIN MADCAM-1 [J].
BERLIN, C ;
BERG, EL ;
BRISKIN, MJ ;
ANDREW, DP ;
KILSHAW, PJ ;
HOLZMANN, B ;
WEISSMAN, IL ;
HAMANN, A ;
BUTCHER, EC .
CELL, 1993, 74 (01) :185-195
[5]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[6]   Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease [J].
Biancheri, Paolo ;
Brezski, Randall J. ;
Di Sabatino, Antonio ;
Greenplate, Allison R. ;
Soring, Keri L. ;
Corazza, Gino R. ;
Kok, Klaartje B. ;
Rovedatti, Laura ;
Vossenkaemper, Anna ;
Ahmad, Nadja ;
Snoek, Susanne A. ;
Vermeire, Severine ;
Rutgeerts, Paul ;
Jordan, Robert E. ;
MacDonald, Thomas T. .
GASTROENTEROLOGY, 2015, 149 (06) :1564-+
[7]   Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis [J].
Brandse, Johannan F. ;
van den Brink, Gijs R. ;
Wildenberg, Manon E. ;
van der Kleij, Desiree ;
Rispens, Theo ;
Jansen, Jeroen M. ;
Mathot, Ron A. ;
Ponsioen, Cyriel Y. ;
Lowenberg, Mark ;
D'Haens, Geert R. A. M. .
GASTROENTEROLOGY, 2015, 149 (02) :350-+
[8]   Personalizing medicine for autoimmune and inflammatory diseases [J].
Chan, Andrew C. ;
Behrens, Timothy W. .
NATURE IMMUNOLOGY, 2013, 14 (02) :106-109
[9]   Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].
Colombel, Jean Frederic ;
Sandborn, William J. ;
Reinisch, Walter ;
Mantzaris, Gerassimos J. ;
Kornbluth, Asher ;
Rachmilewitz, Daniel ;
Lichtiger, Simon ;
D'Haens, Geert ;
Diamond, Robert H. ;
Broussard, Delma L. ;
Tang, Kezhen L. ;
van der Woude, C. Janneke ;
Rutgeerts, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395
[10]   Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65